I have not sold anything only because I own all my shares under the current PPS and would be foolish to sell. I feel that even with lawsuits we can get above 4 in the next 3-6 months with next quarter numbers being higher due to abstral and we will be getting closer to trial results. This will be toxic for at least another 3 months.
I am in since 1.93 and I am not going anywhere. This company will be fine. The lawsuits are fake. And the investigation will find no wrong doing against Gale. By then the next ER will be coming out and the numbers will be better. And back up we go
95K shares. in since 8/12. I have 10 years to retirement. I look forward to the next few years.
Cancer survivor. I like the cause and I like making money with the investment.
Sentiment: Strong Buy
same here. about 2 years or a little more. First got in at 1.60 i think. the people who have the problems bought the hype over 6 and are of course crying, but those of us with an average of say 3 have nothing to complain about. We just were here early and will stick it out along with the institutions who are all in under 3.
Abstral will prove to be the savior here. It is the best in class by far and is starting to gain serious traction amongst prescribers, especially after the free/covered co-pay Rx coupon program Galena instituted. Again, Insys did the same thing with Subsys - provided free Rx with coupons to take to the pharmacy with their prescription, and look at their stock price today. All of your logic is dead on. This all sucks, but the stock will still be a big winner before Christmas. All one has to do is look at INSY. Yes, INSY has better management and to have great management, you must pay a premium stock price, but Abstral beats the pants off of Subsys amongst patients as well as physician preference and that is why you are seeing the upward guidance. GALE stock price will mimic that of what the INSY stock chart has done over the last 12 months. It takes cahonas to aggressively buy at times like this, but those who do will be rewarded in 2014 in my opinion. And this is not even factoring in the other products in the pipeline, like Neuvax. That's a down the road plus, which, if and when favorable Phase III data is released, will send the price soaring to $100+. in my opinion...Longs, stay long. The science (and pipeline) has not changed. The reasons we bought in have not changed.......
Sentiment: Strong Buy